Fibrinogen, fibrinolysis and diabetes mellitus: a comment.
Vague
P
P
Diabetes Department, University Hospital Timone, Marseille, France.
Juhan-Vague
I
I
D001161:Arteriosclerosis / Q000453:epidemiology / Q000503:physiopathology*; D015415:Biomarkers / Q000097:blood; D003922:Diabetes Mellitus, Type 1 / Q000503:physiopathology*; D003924:Diabetes Mellitus, Type 2 / Q000503:physiopathology*; D003925:Diabetic Angiopathies / Q000453:epidemiology / Q000503:physiopathology*; D005340:Fibrinogen / Q000502:physiology*; D005342:Fibrinolysis; D006801:Humans; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D012307:Risk Factors; D010959:Tissue Plasminogen Activator / Q000097:blood
D015415:Biomarkers; D017395:Plasminogen Activator Inhibitor 1; D005340:Fibrinogen; D010959:Tissue Plasminogen Activator